[4:09 PM] Deep, Akash (External)
def extract_table_of_contents(file_path):
    """
    Extracts the table of contents from a PDF file and saves it as JSON.
    :param file_path: Path to the PDF file.
    """
    logger.info("extracting table of content")
   
    text = extract_text(pdf_file=file_path, page_numbers=[i for i in range(11)])
 
   
       
 
 
    lines = text.split("\n")
    lines = [line.rstrip() for line in lines if line.strip()]
    table_of_contents = []
 
    toc_regex = re.compile(r'^\d+(\.\d)*\.\s.*\.\.{3,}\d+$')
    print("toc_regex",lines)
 
    for line_num in range(len(lines) - 1):
        if lines[line_num] and not (lines[line_num][-1].isdigit()):
            line = lines[line_num] + " " + lines[line_num + 1]
        else:
            line = lines[line_num]
        match = re.search(toc_regex, line)
        if match:
            table_of_contents.append(line)
    print("table_of_contents",table_of_contents)
 
    if len(table_of_contents) == 0:
        raise InvalidPdfException(data=file_path.split("/")[-1])
 
    section_headings = format_table_of_contents(table_of_contents)
 
    return section_headings
 
[4:10 PM] Deep, Akash (External)
toc_regex ['Interim Full Clinical Study Report', 'Protocol B7841007', 'TITLE PAGE', 'INTERIM CLINICAL STUDY REPORT', 'Study Title:', 'An Open-Label Extension Study to Evaluate the', 'Long-Term Safety, Tolerability, and Efficacy of', 'Marstacimab Prophylaxis in Severe (Coagulation', 'Factor Activity <1%) Hemophilia A Participants', 'With or Without Inhibitors or Moderately Severe to', 'Severe Hemophilia B Participants (Coagulation', 'Factor Activity ≤2%) With or Without Inhibitors', 'Study Number:', 'Study Phase:', 'Compound:', 'Indication:', 'B7841007', '3', 'Marstacimab (PF-06741086)', 'Hemophilia A, Hemophilia B', 'Study Sponsor:', 'Pfizer Inc.', 'Sponsor’s Signatory:', 'John Teeter, MD - Global Clinical Lead', 'Name and Affiliation of', 'Principal or', 'Coordinating/Leading', 'Investigator:', 'Davide Matino, MD, MSc', 'Hamilton Health Sciences – McMaster University', 'Medical Centre', 'Health Information Research Unit', '1200 Main Street West', 'Hamilton, Ontario, L8N3Z5', 'Canada', 'PFIZER CONFIDENTIAL', 'Page 1', 'Page 1', '090177e19e03e1fc\\Approved\\Approved On: 13-Jul-2023 04:00 (GMT)', 'Interim Full Clinical Study Report', 'Protocol B7841007', 'Study Initiation Date:', 'First Participant First Visit (FPFV):', '17 November 2021', 'Interim Data Cutoff Date:', 'The analyses presented in this report are based on a', 'database lock date of 10 March 2023', 'Regulatory Agency or', 'Public Disclosure Identifier', 'Number:', 'US IND Number: 126734', 'EudraCT Number: 2021-001951-15', 'EU CT Number: 2022-500470-33-00', 'ClinicalTrials.gov ID: NCT05145127', 'CSR Version and Report', 'Date:', 'Document Version', 'Interim CSR Version 1.0', 'Report Date', '12 July 2023', 'GOOD CLINICAL PRACTICE STATEMENT', 'This study was conducted in compliance with GCP guidelines and, where applicable,', 'local country regulations relevant to the use of new therapeutic agents in the', 'country/countries of conduct, including the archiving of essential documents.', 'PFIZER CONFIDENTIAL', 'Page 2', 'Page 2', '090177e19e03e1fc\\Approved\\Approved On: 13-Jul-2023 04:00 (GMT)\x0cInterim Full Clinical Study Report', 'Protocol B7841007', 'SYNOPSIS', 'TABLE OF CONTENTS', 'The sections in this CSR are numbered 1 through 7, 14, and 16. There are no sections', 'numbered 8 to 13, or 15. The numbering for Sections 14 and 16 are retained', 'corresponding to the ICH E3 structure.', 'TITLE PAGE......................................................................................................................... 1', 'SYNOPSIS............................................................................................................................. 3', 'TABLE OF CONTENT......................................................................................................... 3', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS........................................', '13', '15', 'ETHICS..................................................................................................................................', 'Independent Ethics Committee and/or Institutional Review Board...................................', '15', 'Ethical Conduct of the Study..............................................................................................', '15', '15', 'Participant Information and Consent..................................................................................', '1. INTRODUCTION .............................................................................................................', '15', '17', '2. STUDY OBJECTIVES, ENDPOINTS AND ESTIMANDS............................................', '3. INVESTIGATIONAL PLAN............................................................................................', '19', '3.1. Overview of Study Design ..........................................................................................', '19', '20', '3.1.1. Discussion of Study Design ..................................................................................', '20', '3.1.2. Changes in Study Conduct....................................................................................', '21', '3.2. Investigators and Study Administrative Structure.......................................................', '21', '3.3. Selection of Study Population .....................................................................................', '21', '3.3.1. Inclusion/Exclusion Criteria..................................................................................', '21', '3.3.2. Removal of Participants From Intervention or Study ...........................................', '21', '3.4. Study Intervention .......................................................................................................', '21', '3.4.1. Study Interventions Administered.........................................................................', '22', '3.4.1.1. Identity of Study Intervention.........................................................................', '22', '3.4.2. Measures to Minimize Bias...................................................................................', '22', '3.4.3. Study Intervention Compliance.............................................................................', '22', '3.4.4. Prior and Concomitant Therapy............................................................................', '23', '3.5. Study Assessments and Procedures.............................................................................', '23', '3.5.1. Planned Measurements and Timing of Assessments ............................................', '23', '3.5.2. Appropriateness of Measures................................................................................', 'PFIZER CONFIDENTIAL', 'Page 3', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', '3.5.3. Additional Summary of Specific Assessments .....................................................', '3.5.3.1. Efficacy Evaluations.......................................................................................', '3.5.3.2. Pharmacokinetic Evaluations..........................................................................', '3.5.3.2.1. Pharmacokinetic Sampling.......................................................................', '3.5.3.3. Biomarker Evaluations ...................................................................................', '3.5.3.3.1. Biomarker Sampling.................................................................................', '3.5.3.3.2. Biomarker Analytical Methods ................................................................', '3.5.3.4. Immunogenicity Evaluation............................................................................', '3.5.3.4.1. Immunogenicity Sampling .......................................................................', '3.5.3.4.2. Immunogenicity Analytical Methods.......................................................', '3.5.3.5. Other Evaluations and Exploratory Evaluations.............................................', '3.5.3.6. Safety Evaluations ..........................................................................................', '3.5.3.6.1. Adverse Events.........................................................................................', '3.5.3.6.2. Serious Adverse Events............................................................................', '3.5.3.6.3. Laboratory Evaluations ............................................................................', '3.5.3.6.4. Other Safety Measures .............................................................................', '3.5.3.6.4.1. Vital Signs..........................................................................................', '3.5.3.6.4.2. Other Safety Evaluations....................................................................', '3.6. Data Quality Assurance...............................................................................................', '3.6.1. Study Monitoring ..................................................................................................', '3.6.2. Investigator Meetings and Staff Training .............................................................', '3.6.3. Laboratory Procedures ..........................................................................................', '3.6.4. Investigator Responsibilities .................................................................................', '3.6.5. Clinical Data Management....................................................................................', '3.6.6. Clinical Quality Assurance Audits........................................................................', '3.6.7. Quality Tolerance Limits ......................................................................................', '3.7. Statistical Analysis ......................................................................................................', '3.7.1. Statistical Analysis Plan........................................................................................', '3.7.1.1. Analysis Sets...................................................................................................', '3.7.1.2. Determination of Sample Size ........................................................................', '3.7.1.3. Efficacy Analysis............................................................................................', '3.7.1.4. Safety Analysis ...............................................................................................', '3.7.1.5. Pharmacokinetics and Conditional Biomarkers..............................................', '23', '23', '23', '23', '24', '24', '24', '24', '24', '24', '24', '24', '24', '25', '25', '25', '25', '25', '25', '25', '25', '25', '26', '26', '26', '26', '27', '27', '27', '27', '27', '27', '27', 'PFIZER CONFIDENTIAL', 'Page 4', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', '3.7.2. Changes in Planned Analyses Prior to Database Lock .........................................', '3.7.3. Changes Following Study Database Lock and Post Hoc Analyses ......................', '3.8. COVID-19 Summary of Impact ..................................................................................', '4. STUDY PARTICIPANTS.................................................................................................', '4.1. Disposition of Participants ..........................................................................................', '4.2. Important Protocol Deviations.....................................................................................', '4.3. Populations Analyzed..................................................................................................', '4.4. Demographic and Other Baseline Characteristics.......................................................', '4.4.1. Demography and Baseline Characteristics............................................................', '4.4.2. Medical History and Concurrent Illnesses ............................................................', '4.5. Prior and Concomitant Therapy ..................................................................................', '4.5.1. Prior Therapy ........................................................................................................', '4.5.2. Concomitant Therapy............................................................................................', '4.6. Exposure and Study Intervention Compliance ............................................................', '4.6.1. Exposure................................................................................................................', '4.6.2. Dose Modification.................................................................................................', '4.6.3. Compliance With Intervention..............................................................................', '5. EVALUATION OF RESPONSE TO STUDY INTERVENTION ...................................', '5.1. Efficacy........................................................................................................................', '5.1.1. ABR of Treated Bleeds .........................................................................................', '5.1.2. Incidence of Joint Bleeds ......................................................................................', '5.1.3. Incidence of Spontaneous Bleeds..........................................................................', '5.1.4. Incidence of Target Joint Bleeds...........................................................................', '5.1.5. Incidence of Total Bleeds (Treated and Untreated) ..............................................', '5.1.6. Hemophilia Joint Health Score (HJHS) ................................................................', '5.1.7. Number of Target Joints........................................................................................', '5.1.8. Total Coagulation Factor Consumption................................................................', '5.1.9. Health-Related Quality-of-Life Outcomes............................................................', '5.1.9.1. Haem-A-QoL (≥17 years of age) and Haemo-QoL (adolescents 12 to <17', 'years of age)..........................................................................................................', '5.1.9.2. EQ-5D-5L .......................................................................................................', '5.2. Safety...........................................................................................................................', '5.2.1. Adverse Events......................................................................................................', '27', '27', '27', '28', '28', '30', '31', '32', '32', '38', '41', '41', '41', '41', '41', '42', '43', '43', '44', '44', '45', '46', '47', '48', '49', '50', '51', '51', '51', '52', '52', '52', 'PFIZER CONFIDENTIAL', 'Page 5', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', '5.2.1.1. Brief Summary of Adverse Events .................................................................', '5.2.1.1.1. Frequency of TEAEs by SOC, PT and Severity ......................................', '5.2.1.1.2. Frequency of TEAEs by Subgroups.........................................................', '5.2.1.1.3. Treatment-related AEs..............................................................................', '5.2.1.1.4. Frequency of AEs for Participants with Dose Escalation ........................', '5.2.1.2. Deaths (None).................................................................................................', '5.2.1.3. Serious Adverse Events ..................................................................................', '5.2.1.4. Dose Modification and/or Discontinuations from Study Due to Adverse', 'Events ...................................................................................................................', '5.2.1.4.1. Permanent Discontinuations.....................................................................', '5.2.1.4.2. Dose Modification or Temporary Discontinuation ..................................', '5.2.1.5. Adverse Events of Special Interest .................................................................', '5.2.1.5.1. Thromboembolic Events ..........................................................................', '5.2.1.5.2. Thrombotic Microangiopathy...................................................................', '5.2.1.5.3. Disseminated Intravascular Coagulation/Consumption Coagulopathy....', '5.2.1.5.4. Injection Site Reaction .............................................................................', '5.2.1.5.5. Severe Hypersensitivity or Anaphylactic Reactions ................................', '5.2.2. Clinical Laboratory Evaluation.............................................................................', '5.2.2.1. Evaluation of Key Laboratory Parameters......................................................', '5.2.2.1.1. Hemoglobin ..............................................................................................', '5.2.2.1.2. Hematocrit ................................................................................................', '5.2.2.1.3. Liver Function Tests.................................................................................', '5.2.2.1.4. Activated Partial Thromboplastin (sec)....................................................', '5.2.2.1.5. Prothrombin Time (sec)............................................................................', '5.2.2.1.6. Cardiac Troponin I ...................................................................................', '5.2.2.1.7. Fibrinogen.................................................................................................', '5.2.2.1.8. Leukocyte Count ......................................................................................', '5.2.2.1.9. Platelet Count ...........................................................................................', '5.2.2.1.10. Serum Creatinine....................................................................................', '5.2.2.1.11. D-Dimer..................................................................................................', '5.2.3. Other Safety Evaluations.......................................................................................', '5.2.3.1. Vital Signs.......................................................................................................', '5.2.3.2. Electrocardiograms .........................................................................................', '5.2.3.3. Physical Examination Findings ......................................................................', '52', '54', '59', '59', '60', '62', '62', '63', '63', '64', '66', '67', '67', '67', '67', '68', '69', '69', '69', '69', '69', '70', '70', '70', '70', '71', '71', '71', '71', '71', '71', '72', '72', 'PFIZER CONFIDENTIAL', 'Page 6', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', '5.2.3.4. Safety Observations Related to the PFP or PFS .............................................', '5.3. Pharmacokinetics and Conditional Biomarkers ..........................................................', '5.4. Genetics .......................................................................................................................', '5.5. Immunogenicity...........................................................................................................', '5.6. Summary of Evaluation of Response to Study Intervention .......................................', '6. CONCLUSIONS................................................................................................................', '7. REFERENCES ..................................................................................................................', '72', '72', '73', '73', '76', '77', '78', 'LIST OF TABLES', 'Table 1. Study Objectives and Endpoints.............................................................................', 'Table 2. Study Intervention(s) Administered .......................................................................', 'Table 3. Disposition Events Summary .................................................................................', 'Table 4. Summary of Important Protocol Deviations - Enrolled Set ...................................', 'Table 5. Participant Evaluation Groups................................................................................', 'Table 6. Demographic Characteristics - Safety Analysis Set...............................................', 'Table 7. Participant Characteristics and Hemophilia History - Safety Analysis Set............', 'Table 8. General Medical History - Safety Analysis Set......................................................', 'Table 9. Summary of Study Treatment Exposure - Safety Analysis Set..............................', 'Table 10. Summary of ABR for Treated Bleeds - Safety Analysis Set................................', 'Table 11. Summary of Incidence of Joint Bleeds - Safety Analysis Set..............................', 'Table 12. Summary of Incidence of Spontaneous Bleeds - Safety Analysis Set .................', 'Table 13. Summary of Incidence of Target Joint Bleeds - Safety Analysis Set...................', 'Table 14. Summary of Incidence of Total Bleeds (Treated and Untreated) - Safety', 'Analysis Set...................................................................................................................', 'Table 15. Summary of Number of Target Joints - Safety Analysis Set ...............................', 'Table 16. Summary of Adverse Events (All Causalities) - Safety Analysis Set..................', 'Table 17. Summary of Treatment-Emergent Adverse Events by MedDRA System', 'Organ Class, Preferred Term, and CTCAE Grade (All Causalities) for Overall -', 'Safety Analysis Set........................................................................................................', 'Table 18. Summary of Treatment-Emergent Adverse Events by MedDRA System', 'Organ Class, Preferred Term, and CTCAE Grade (All Causalities) for Non-', 'Inhibitor On-Demand - Safety Analysis Set..................................................................', 'Table 19. Summary of Treatment-Emergent Adverse Events by MedDRA System', 'Organ Class, Preferred Term, and CTCAE Grade (All Causalities) for Non-', 'Inhibitor Prophylaxis - Safety Analysis Set ..................................................................', '18', '22', '29', '31', '32', '33', '35', '38', '41', '44', '45', '46', '47', '49', '50', '53', '55', '56', '57', 'PFIZER CONFIDENTIAL', 'Page 7', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', 'Table 20. Summary of Treatment-Emergent Adverse Events by MedDRA System', 'Organ Class and Preferred Term (Treatment Related) -Safety Analysis Set................', 'Table 21. Treatment-Emergent Adverse Events by System Organ Class, Preferred Term', 'and Age Group (All Causalities) During Marstacimab 300 mg QW Dose - Safety', 'Analysis Set...................................................................................................................', 'Table 22. Summary of Serious Adverse Events by System Organ Class and Preferred', 'Term - Safety Analysis Set............................................................................................', 'Table 23. Summary of Temporary Participant Discontinuations or Dose Reductions', 'Due to Adverse Events by Age Group - Safety Analysis Set .......................................', 'Table 24. Adverse Events of Special Interest - Safety Analysis Set ....................................', 'Table 25. Summary of Injection Site Reaction - Max CTCAE Grade for Non-Inhibitor', 'Prophylaxis - Safety Analysis Set .................................................................................', 'Table 26. Overall Incidence of Anti-Marstacimab Antibody (ADA) and Neutralizing', 'Antibody (NAb) by Age Group - Marstacimab Safety Set...........................................', '60', '61', '63', '65', '66', '68', '74', 'PFIZER CONFIDENTIAL', 'Page 8', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', '14.1 Demographic Data', '14.2 Efficacy Data Summary', '14. TABLES AND FIGURES REFERRED TO BUT NOT INCLUDED IN THE TEXT ..', '79', 'Table 14.1.3.2 Significant Medical History - Safety Analysis Set  ................................', '80', 'Table 14.2.1.2.6 Summary of Hemophilia Joint Health Score (HJHS)* - Safety', 'Analysis Set .............................................................................................................', 'Table 14.2.1.3.1 Summary of Observed Values of Haem-A-QoL * - Safety Analysis', 'Set ............................................................................................................................', 'Table 14.2.1.3.2 Change from Baseline in Haem-A-QoL * - Safety Analysis Set.........', 'Table 14.2.1.3.3 Summary of Observed Values of Haemo-Qol * - Safety Analysis Set', 'Table 14.2.1.3.4 Change from Baseline in Haemo-QoL * - Safety Analysis Set...........', 'Table 14.2.1.3.5 Summary of EQ-5D - Safety Analysis Set...........................................', 'Table 14.2.1.4 Summary of Factor Replacement Consumption - Safety Analysis Set ..', '14.3 Safety Data Summary', '14.3.1 Adverse Events', 'Table 14.3.1.1.1 Summary of Treatment-Emergent Adverse Events (All', 'Causalities) - Safety Analysis Set.........................................................................', 'Table 14.3.1.1.1.1 Summary of Treatment-Emergent Adverse Events (All', 'Causalities) During Marstacimab 300 mg QW Dose - Safety Analysis Set ........', 'Table 14.3.1.1.2.1 Summary of Adverse Events (Device related) -Safety Analysis', 'Set .........................................................................................................................', 'Table 14.3.1.1.3 Summary of Treatment Emergent Adverse Events (Treatment', 'Related)-Safety Analysis Set................................................................................', 'Table 14.3.1.1.4 Listing of Participant Discontinuations Due to Adverse Events -', 'Safety Analysis Set...............................................................................................', 'Table 14.3.1.1.5 Listing of Temporary Discontinuations or Dose Reductions Due to', 'Adverse Events -Safety Analysis Set ...................................................................', 'Table 14.3.1.1.7 Medication Errors -Safety Analysis Set ...........................................', 'Table 14.3.1.2.3 Treatment-Emergent Adverse Events by System Organ Class,', 'Preferred Term and Age Group (All Causalities) -Safety Analysis Set...............', 'Table 14.3.1.2.7 Listing of Adverse Event of Special Interests -Safety Analysis Set.', 'Table 14.3.1.3.2.1 Summary of Injection Site Reaction - Max CTCAE Grade for', 'Non-Inhibitor On-Demand - Safety Analysis Set.................................................', 'Table 14.3.1.3.2.3 Summary of Injection Site Reaction - Max CTCAE Grade for', 'Overall - Safety Analysis Set................................................................................', 'Table 14.3.1.3.3 Summary of COVID-19 related AEs by System Organ Class and', 'Preferred Term – Safety Analysis Set ..................................................................', '14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events', 'Table 14.3.2.2.1 Individual Listing of Deaths -Safety Analysis Set ...........................', '231', '88', '91', '113', '146', '159', '185', '191', '192', '194', '196', '198', '200', '201', '204', '205', '209', '228', '229', '230', 'PFIZER CONFIDENTIAL', 'Page 9', '\x0cInterim Full Clinical Study Report', 'Protocol B7841007', 'Events', 'Table 14.3.2.2.2 Listing of Serious Adverse Events -Safety Analysis Set..................', '232', '14.3.3 Narratives of Deaths, Other Serious and Certain Other Significant Adverse', 'B7841007 (Marstacimab_PF-06741086) Narratives of Deaths, Other Serious and', 'Other Adverse Events (Non-Inhibitor) Interim 2 Clinical Study Report .............', '234', '14.3.4 Abnormal Laboratory Value Listings', 'Table 14.3.4.1.1 Marstacimab Laboratory Data Hematology - Shift Tables - Safety', 'Analysis Set ..........................................................................................................', 'Table 14.3.4.1.2 Laboratory Data Clinical Chemistry - Shift Tables -Safety', 'Analysis Set ..........................................................................................................', 'Table 14.3.4.1.4 Marstacimab Laboratory Test Data - Changes from Baseline by', 'Visit - Safety Analysis Set....................................................................................', 'Figure 14.3.4.1.5 eDISH Plot for Alanine Aminotransferase (ALT) (All Safety Set)', 'Figure 14.3.4.1.6 eDISH Plot for Aspartate Aminotransferase (AST) (All Safety', 'Set)........................................................................................................................', 'Table 14.3.4.2 Incidence of Laboratory Test Abnormalities - All Safety Set .............', '309', '348', '388', '507', '508', '509', 'Table 14.3.5.1 Summary of Vital Signs Data - Safety Analysis Set ...........................', '510', '14.3.5. Vital Signs Data', '14.3.6. ECG Data', 'Table 14.3.6.1 Summary of ECG Results -Safety Analysis Set..................................', 'Table 14.3.6.2 Categorization Summary of ECG Data -Safety Analysis Set..............', '518', '526', '14.4 Dosing, PK, Concomitant and Previous Drug AND Non-Drug Treatments Data', 'Table 14.4.1.1.1 Summary of Marstacimab 300 mg QW Exposure - Safety Analysis', 'Set ............................................................................................................................', 'Table 14.4.1.2 Summary of Concomitant Factor Replacement Treatment by Reason -', 'Safety Analysis Set ..................................................................................................', 'Table 14.4.2 Summary of concomitant Drug Use - Safety Analysis Set........................', 'Table 14.4.3 Concomitant Nondrug Treatments/Procedures -Safety Analysis Set ........', '527', '530', '534', '545', 'ERRATA', 'PFIZER CONFIDENTIAL', 'Page 10', 'Interim Full Clinical Study Report', 'Protocol B7841007', '16. APPENDICES', '16.1. Study Information', '16.1.1. Protocol', '16.1.2. Sample Case Report Form(s)/Data Collection Tool(s)', '16.1.3. List of Independent Ethics Committee (IEC) or Institutional Review', 'Board (IRB) and Sample Standard Participant Information Sheet and', 'Informed Consent Document (ICD).', '16.1.4. List and Description of Investigators and Other Service Providers.', '16.1.5. Signatures of Principal or Coordinating/Leading Investigator(s) or', "Sponsor's Responsible Medical Officer, Depending on the Regulatory", "Authority's Requirement", '16.1.5.1. Sponsor Signatures', '16.1.5.2. CSR Investigator Declaration', '16.1.6. Study Drug Information Listing of Participants Receiving Study', 'Intervention From Specific Batches (When More Than One Batch Was', 'Used)', '16.1.7. Randomization Codes/Randomization Scheme and Codes', '16.1.8. Audit Certificates', '16.1.9. Documentation of Statistical Methods', '16.1.10. Documentation of Inter-Laboratory Standardization Methods (Not', 'Applicable)', '16.1.11. Publications Based on the Study (None)', '16.1.12. Important Publications Referenced in the Report (None)', '16.1.13. Independent Oversight Committees', '16.2. Participant Data Listings', '16.2.1. Discontinued Participants', '16.2.2. Protocol Deviations', '16.2.3. Participants Excluded From the Efficacy Analysis (None)', '16.2.4. Demographic Data', '16.2.5. Compliance and/or Drug Concentration Data', '16.2.5.10 Other Documents with Patient-Level Data', '16.2.6. Individual Efficacy Response Data', '16.2.7. Adverse Event Listing by Participant', 'PFIZER CONFIDENTIAL', 'Page 8', 'Page 11', '090177e19e03e1fc\\Approved\\Approved On: 13-Jul-2023 04:00 (GMT)']table_of_contents []
 
[4:10 PM] Deep, Akash (External)
InvalidPdfException.__init__() got an unexpected keyword argument 'data'
 
